Equity Overview
Price & Market Data
Price: $0.39
Daily Change: -$0.00464 / 1.19%
Daily Range: $0.325 - $0.41
Market Cap: $35,017,468
Daily Volume: 2,510,557
Performance Metrics
1 Week: -1.13%
1 Month: 17.22%
3 Months: 128.5%
6 Months: 172.3%
1 Year: 146.9%
YTD: 138.1%
Details
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; as well as holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.